Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Полное описание

Библиографические подробности
Главные авторы:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Другие авторы:	BSH Committee
Формат:	Journal article
Язык:	English
Опубликовано:	Wiley 2023

Схожие документы

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
по: McMullin, M, и др.
Опубликовано: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
по: McMullin, M, и др.
Опубликовано: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
по: McLornan, D, и др.
Опубликовано: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
по: Reilly, J, и др.
Опубликовано: (2014)

Guideline for the diagnosis and management of myelofibrosis.
по: Reilly, J, и др.
Опубликовано: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
по: Bassiony S, и др.
Опубликовано: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
по: Verstovsek, S, и др.
Опубликовано: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
по: P. Harrington, и др.
Опубликовано: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
по: Mead, AJ, и др.
Опубликовано: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
по: Salisbury, RA, и др.
Опубликовано: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
по: Mclornan, D, и др.
Опубликовано: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
по: Mesa, RA, и др.
Опубликовано: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
по: Ken I. Mills, и др.
Опубликовано: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
по: Reilly, J, и др.
Опубликовано: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
по: Reilly, J, и др.
Опубликовано: (2014)

Low-dose thalidomide in myelofibrosis
по: Robert Weinkove, и др.
Опубликовано: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
по: Mead, A, и др.
Опубликовано: (2019)

Guideline for the investigation and management of eosinophilia
по: Butt, N, и др.
Опубликовано: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
по: Donal P. McLornan, и др.
Опубликовано: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
по: Stephen T. Oh, и др.
Опубликовано: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
по: Ruben A. Mesa, и др.
Опубликовано: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
по: Ruben A. Mesa, и др.
Опубликовано: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
по: Harrison, C, и др.
Опубликовано: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
по: McIlroy, G, и др.
Опубликовано: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
по: Harrison, C, и др.
Опубликовано: (2016)

The soldier and the post-conflict state
по: McMullin, J, и др.
Опубликовано: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
по: Cross, NCP, и др.
Опубликовано: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
по: Harrison, C, и др.
Опубликовано: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
по: McPherson, S, и др.
Опубликовано: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
по: Adam J. Mead, и др.
Опубликовано: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
по: Niall P. Kelly, и др.
Опубликовано: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
по: Psaila, B, и др.
Опубликовано: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
по: Sousos, N, и др.
Опубликовано: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
по: Graham McIlroy, и др.
Опубликовано: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
по: A. Vannucchi, и др.
Опубликовано: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
по: Chowdhury, O, и др.
Опубликовано: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
по: Sousos, N, и др.
Опубликовано: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
по: Greenfield, G, и др.
Опубликовано: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
по: F. Passamonti, и др.
Опубликовано: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
по: Butt, N, и др.
Опубликовано: (2019)